冠脉抗栓论坛-1

Coronary Antithrombosis Forum-1

11/21 13:30-15:30

102C (102C)

13:30- 15:30

主持

Roopali KHANNA (Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), India), 李毅(LI Yi) (中国人民解放军北部战区总医院), 刘震宇(LIU Zhen-Yu) (中国医学科学院北京协和医院), 戴宇翔(DAI Yu-Xiang) (复旦大学附属中山医院)
14:30-14:50

高危急性冠脉综合征患者的降阶抗栓治疗：现状与展望

De-escalated Anti-thrombotic Therapy for High-risk ACS Population: Current Evidence and Future Prospects

Roxana MEHRAN (The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai)
14:50-15:10

优化抗板方向-OPT-PEACE/EA-OUTCOME/TARGET SAFE等

Navigating the Future of Antiplatelet Therapy: Balancing Efficacy and Safety from the OPT-PEACE Study

韩雅玲(HAN Ya-Ling) (中国人民解放军北部战区总医院)
13:30-13:50

ULTIMATE-DAPT研究揭示：ACS患者PCI后早期转为替格瑞洛单药的疗效

Ticagrelor alone Versus Ticagrelor Plus Aspirin from Month 1 to Month 12 after Percutaneous Coronary Intervention in Patients with Acute Coronary Syndromes (ULTIMATE-DAPT)

陈绍良(CHEN Shao-Liang) (南京市第一医院)
13:50-14:10

REC-CAGEFREE II试验结果：DCB治疗后短期DAPT接替格瑞洛单药是否可行？

Randomized Evaluation of 5-Month Ticagrelor Monotherapy After 1-Month Dual-Antiplatelet Therapy in Patients With Acute Coronary Syndrome Treated With Drug-Coated Balloons: REC-CAGEFREE II Trial

陶凌(TAO Ling) (空军军医大学西京医院)
14:10-14:30

PCI术后抗血小板治疗：面对众多选择，我们如何决策？

Antiplatelet Therapy after PCI—So Many Options

David MOLITERNO (University of Kentucky Medical Center, USA)
15:10-15:30

讨论

Discussion

打印